PBYI
NASDAQ · Biotechnology
Puma Biotechnology Inc
$7.74
-2.03 (-20.78%)
Financial Highlights (FY 2026)
Revenue
245.95M
Net Income
33.51M
Gross Margin
74.5%
Profit Margin
13.6%
Rev Growth
+0.1%
D/E Ratio
0.17
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 74.5% | 74.5% | 67.8% | 67.8% |
| Operating Margin | 16.3% | 14.7% | 23.2% | 29.3% |
| Profit Margin | 13.6% | 12.9% | 18.7% | 21.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 245.95M | 245.82M | 42.11M | 46.96M |
| Gross Profit | 183.30M | 183.21M | 28.56M | 31.85M |
| Operating Income | 40.16M | 36.13M | 9.75M | 13.74M |
| Net Income | 33.51M | 30.14M | 7.89M | 10.24M |
| Gross Margin | 74.5% | 74.5% | 67.8% | 67.8% |
| Operating Margin | 16.3% | 14.7% | 23.2% | 29.3% |
| Profit Margin | 13.6% | 12.9% | 18.7% | 21.8% |
| Rev Growth | +0.1% | +0.1% | +7.6% | -6.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 31.11M | 31.11M | 115.20M | 98.43M |
| Total Equity | 180.01M | 180.01M | 249.14M | 242.47M |
| D/E Ratio | 0.17 | 0.17 | 0.46 | 0.41 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 51.95M | 49.33M | 13.15M | 15.14M |
| Free Cash Flow | — | — | 4.76M | 6.11M |